Autoimmune diabetes vaccine (Diamyd Medical)

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug NameAutoimmune diabetes vaccine (Diamyd Medical)
Drug Alias NameGAD-Alum vaccineAntigen-based therapy (ABT)Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel® (Diamyd Medical)rhGAD65/alumDiamyd +[7] 
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsAutoimmune DiseasesImmune System DiseasesEndocrine System Diseases +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesSweden +[15] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesDiamyd Medical Ab
China Registration ClassN/A

Develop Information

Active CompaniesNorwegian University Of Science And TechnologyLinkoeping UniversityDiamyd Medical Ab
Inactive CompaniesDiamyd Therapeutics AbNational Institute Of Diabetes And Digestive And Kidney DiseasesLund University
Active IndicationsAutoimmune DiseasesLatent Autoimmune Diabetes in AdultsDiabetes Mellitus, Type 1
Inactive IndicationsImmune System DiseasesEndocrine System DiseasesPrediabetic State +[6] 

Other Information

ATC CodeN/A
Related LinksN/A